Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Hyaluronidase/immune-globulin

Aseptic meningitis and deep vein thrombosis: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Rubinstein A, et al. Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA. Clinical Immunology 250: May 2023. Available from: URL: http://doi.org/10.1016/j.clim.2023.109424 [abstract] Rubinstein A, et al. Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA. Clinical Immunology 250: May 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​clim.​2023.​109424 [abstract]
Metadaten
Titel
Hyaluronidase/immune-globulin
Aseptic meningitis and deep vein thrombosis: 2 case reports
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41468-5

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Amiodarone

Case report

Denosumab

Case report

Tacrolimus